Aprea Therapeutics, Inc. (NASDAQ:APRE) Sees Large Growth in Short Interest

Aprea Therapeutics, Inc. (NASDAQ:APRE) was the recipient of a significant increase in short interest in January. As of January 31st, there was short interest totalling 44,900 shares, an increase of 271.1% from the January 15th total of 12,100 shares. Approximately 0.9% of the company’s stock are sold short. Based on an average daily volume of 28,300 shares, the short-interest ratio is presently 1.6 days.

Institutional Inflows and Outflows

Hedge funds have recently made changes to their positions in the business. Dimensional Fund Advisors LP acquired a new position in shares of Aprea Therapeutics during the second quarter valued at about $45,000. LPL Financial LLC acquired a new position in shares of Aprea Therapeutics during the fourth quarter valued at about $53,000. Finally, Landscape Capital Management L.L.C. acquired a new position in shares of Aprea Therapeutics during the fourth quarter valued at about $116,000. 34.19% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

Separately, HC Wainwright reaffirmed a “buy” rating and issued a $20.00 price target on shares of Aprea Therapeutics in a research note on Wednesday, January 15th.

Aprea Therapeutics Price Performance

Shares of NASDAQ APRE opened at $3.43 on Thursday. The stock has a market capitalization of $18.62 million, a P/E ratio of -1.22 and a beta of 0.76. The company has a 50-day moving average price of $3.62 and a 200-day moving average price of $3.44. Aprea Therapeutics has a 1 year low of $2.15 and a 1 year high of $8.85.

Aprea Therapeutics Company Profile

Aprea Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel synthetic lethality-based cancer therapeutics that targets DNA damage response pathways. Its lead product candidate is the ATRN-119 that is in Phase I clinical trials for treating advanced solid tumors.